KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) FCF Margin (2016 - 2025)

Neogenomics' FCF Margin history spans 16 years, with the latest figure at 3.43% for Q4 2025.

  • For Q4 2025, FCF Margin fell 2567.0% year-over-year to 3.43%; the TTM value through Dec 2025 reached 2.99%, down 390.0%, while the annual FY2025 figure was 2.99%, 390.0% down from the prior year.
  • FCF Margin reached 3.43% in Q4 2025 per NEO's latest filing, down from 0.3% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 24.71% in Q4 2021 to a low of 46.23% in Q3 2021.
  • Average FCF Margin over 5 years is 6.76%, with a median of 7.08% recorded in 2022.
  • The largest YoY upside for FCF Margin was 2909bps in 2021 against a maximum downside of -4039bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 24.71% in 2021, then crashed by -124bps to 5.93% in 2022, then soared by 216bps to 6.9% in 2023, then surged by 222bps to 22.24% in 2024, then crashed by -115bps to 3.43% in 2025.
  • Per Business Quant, the three most recent readings for NEO's FCF Margin are 3.43% (Q4 2025), 0.3% (Q3 2025), and 7.72% (Q2 2025).